StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

Mineralys Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Mineralys Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $301.59M, up 72.6% year over year. For fiscal 2025 it was $132.01M, down 21.7% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$132.01M-21.7%
FY2024Dec 31, 2024$168.58M+139.6%
FY2023Dec 31, 2023$70.36M+168.0%
FY2022Dec 31, 2022$26.25M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$221.38M+478.3%
Q1 FY2026Mar 31, 2026$24.37M-35.7%
Q4 FY2025Dec 31, 2025$24.40M-45.2%
Q3 FY2025Sep 30, 2025$31.45M-41.7%
Q2 FY2025Jun 30, 2025$38.28M-2.5%
Q1 FY2025Mar 31, 2025$37.88M+23.2%
Q4 FY2024Dec 31, 2024$44.57M+88.2%
Q3 FY2024Sep 30, 2024$53.99M+139.9%
Q2 FY2024Jun 30, 2024$39.27M+230.5%
Q1 FY2024Mar 31, 2024$30.75M+150.2%
Q4 FY2023Dec 31, 2023$23.69M+203.0%
Q3 FY2023Sep 30, 2023$22.50M+271.3%
Q2 FY2023Jun 30, 2023$11.88M+112.4%
Q1 FY2023Mar 31, 2023$12.29M+81.4%
Q4 FY2022Dec 31, 2022$7.82M–
Q3 FY2022Sep 30, 2022$6.06M–
Q2 FY2022Jun 30, 2022$5.60M–
Q1 FY2022Mar 31, 2022$6.78M–

More Mineralys Therapeutics figures

See a number that looks wrong?